Sartorius announced the 2.4 billion euro acquisition of Polyplus. Polyplus is producing transfection reagents and generates 100 million euros in revenues. The acquisition appears to be very expensive ...

Warburg Pincus notched a hefty gain on its 2020 investment in gene-therapy technology company Polyplus-transfection SA, the latest in a string of healthcare transactions with big payoffs for the ...

Healthcare specialist ArchiMed has made a roughly 300x return for its debut private equity vehicle on its full exit of Polyplus, a developer of technology used in gene and cell therapy. ArchiMed and ...

German life sciences group Sartorius announced it will acquire French drug manufacturer Polyplus for €2.4 billion, or $2.6 billion. Founded in 2001, Polyplus has 270 employees and develops ...

Warburg Pincus agreed to sell Polyplus for €2.4 billion earlier than expected, with the company in high demand despite a challenging exit market – one that requires more “bespoke” approaches, managing ...

Sartorius Stedim Biotech agreed to buy Polyplus, a maker of components for cell and gene therapies, for about €2.4 billion ($2.6 billion) from a group of private investors. The deal would bolster ...

March 31 (Reuters) - Sartorius (SATG.DE), opens new tab will acquire French lab technology company Polyplus for 2.4 billion euros ($2.62 billion) from private investors to strengthen its activities ...

Transfection is a crucial non-viral technique for introducing DNA or RNA into cells, yet achieving high efficiency and consistency can be challenging, particularly with difficult cell types.

Transfection, a key genetic technology in the toolbox of many researchers, spans numerous applications—production of recombinant proteins and recombinant cell lines, drug discovery, delivery of ...